摘要
目的观察低分子肝素联合血管转换酶抑制剂对糖尿病肾病显性蛋白尿的治疗效果。方法将64例糖尿病肾病显性蛋白尿患者随机分为A、B、C3组。A组常规降血糖和饮食控制及对症治疗;B组在A组的基础上加用低分子肝素2500U皮下注射,2次/d;C组在A组的基础上加用洛汀新10mg口服,2次/d;D组在A组的基础上加用低分子肝素2500U皮下注射,2次/d,同时给予洛汀新10mg口服,2次/d。观察治疗前后24h尿蛋白定量、血清白蛋白(ALB)、血肌酐(Scr)、内生肌酐清除率(Ccr)的变化。结果A组病情改善不明显,部分病例有不同程度的恶化;B组及C组24h蛋白尿定量均有明显下降、ALB明显升高,Ccr有轻度下降,但不明显。D组24h蛋白尿明显下降,ALB及Ccr均明显升高。结论低分子肝素联合血管转换酶抑制剂对糖尿病肾病显性蛋白尿的治疗有明显效果,且优于单用LMWH或单用血管转换酶抑制剂。
Objective To investigate the effects of the combination of low molecular weight heparin and ACEI on albuminuria in diabetic nephropathy.Methods 54 cases of diabetic nephropathy with albuminuria were randomly divided into three groups: the control group(A) received oral antidiabetic and diet-control treatment;the first therapeutic group(B) received low molecular weight heparin(2500U,twice daily);the second therapeutic group (C) received Lotensin(10 mg,twice daily); the third therapeutic group(D) received both low molecular weight heparin and Lotensin.therapeutic Three groups also received oral antidiabetic and diet-control treatment.The 24h urine protein,serum albumn(ALB),serum creatinine(Cr) and endogenous creatinine clearance rate(Ccr) of patients in all groups were compared with the levels before treatment.Results The 24 h urine protein significantly decreased after treatment in B,C and D group, but there were no statistical significance In A group. In B and C group,the ALB inceased , but the Ccr changed were no statistical significance. In D group,the ALB and the Ccr increased more significantly.Conclusion The application of the combination of low molecular weight heparin and ACEI on albuminuria in diabetic nephropathy is effective.
出处
《内科》
2006年第2期116-117,共2页
Internal Medicine
